AAFMAA Wealth Management & Trust LLC Sells 7,118 Shares of Boston Scientific Corporation $BSX

Key Points

• AAFMAA Wealth Management & Trust LLC reduced its stake in Boston Scientific Corporation by 29.2%, selling 7,118 shares and bringing its total holdings to 17,231 shares, valued at approximately $1.85 million.
• Insider transactions have shown significant sales, with EVP Arthur C. Butcher selling 17,313 shares for around $1.81 million, which is a 42.32% decrease in his ownership.
• Boston Scientific's recent performance indicates a strong quarterly earnings beat, with revenue of $5.06 billion and an EPS of $0.75, surpassing analyst expectations.

AAFMAA Wealth Management & Trust LLC decreased its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 29.2% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,231 shares of the medical equipment provider's stock after selling 7,118 shares during the period. AAFMAA Wealth Management & Trust LLC's holdings in Boston Scientific were worth $1,851,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. HM Payson & Co. increased its position in shares of Boston Scientific by 1.4% during the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock worth $694,000 after acquiring an additional 98 shares during the period. Park Square Financial Group LLC increased its holdings in Boston Scientific by 5.2% during the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after buying an additional 103 shares during the period. HHM Wealth Advisors LLC grew its stake in Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock valued at $89,000 after purchasing an additional 103 shares during the last quarter. Rise Advisors LLC boosted its stake in Boston Scientific by 13.9% in the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider's stock valued at $85,000 after acquiring an additional 103 shares in the last quarter. Finally, Forum Financial Management LP increased its position in shares of Boston Scientific by 0.8% during the first quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock worth $1,357,000 after purchasing an additional 112 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock valued at $18,397,457 in the last three months. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

Shares of BSX opened at $98.03 on Friday. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a market capitalization of $145.26 billion, a PE ratio of 58.35, a PEG ratio of 2.36 and a beta of 0.65. The stock has a 50-day simple moving average of $103.90 and a 200-day simple moving average of $102.06.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm's revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Raymond James Financial boosted their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Needham & Company LLC reiterated a "buy" rating and set a $121.00 price target on shares of Boston Scientific in a research note on Friday, September 19th. BTIG Research restated a "buy" rating and issued a $127.00 price objective on shares of Boston Scientific in a research note on Tuesday. Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Barclays lifted their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Boston Scientific has an average rating of "Buy" and an average target price of $118.17.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.